Table 5 Previous report on the oncological outcomes of Japanese patients with non-clear cell renal cell carcinoma treated with combination immunotherapy.

From: Efficacy and safety of combination immunotherapy for treating advanced non-clear cell renal cell carcinoma: A multicenter retrospective study in Japan

First author

(year)

Treatment

Patients

n

Sex

(male/female)

Median age

(range)

Histological subtypes

n

(%)

BOR

n (%)

PFS

(mo)

OS

(mo)

TRAE

All grade

n (%)

TRAE

Grade 3/4

n (%)

Izumi18

(2022)

ICI + ICI

22

17/5

64.0

(28.0–87.0)

Papillary

8 (36.4)

CR: 3 (13.6)

PR: 5 (22.7)

SD: 6 (27.3)

PD: 8 (36.4)

6.3

20.8

14 (63.6)

7 (31.8)

Unclassified

6 (27.3)

Chromophobe

3 (13.6)

Bellini duct

2 (9.1)

Translocation

1 (4.5)

ACD-associated

1(4.5)

HLRCC-associated

1 (4.5)

Teishima19

(2024)

ICI + ICI

26

19/7

70.0

(30.0–83.0)

Papillary

14 (53.8)

CR: 3 (11.5)

PR: 6 (23.1)

SD:8 (30.8)

PD: 9 (34.6)

4.6

-

19 (73.1)

12 (46.2)

Sarcomatoid

4 (15.4)

Unclassified

3 (11.5)

Translocated

2 (7.7)

Chromophobe

1 (3.9)

Bellini duct

1 (3.9)

Tubulocystic

1 (3.9)

ACD-associated

0

ICI + TKI

10

8/2

Papillary

5 (50.0)

CR: 0

PR: 3 (30.0)

SD: 4 (40.0)

PD: 3 (30.0)

9.7

-

7 (70.0)

3 (30.0)

Sarcomatoid

2 (20.0)

Unclassified

0

Translocated

0

Chromophobe

1 (10.0)

Bellini duct

0

Tubulocystic

0

ACD-associated

2 (20.0)

Yoshimura20

(2024)

ICI + ICI

20

3/17

64.0

(32.0–83.0)

Papillary

10 (50.0)

CR: 0

PR: 8 (40.0)

SD: 6 (30.0)

PD: 6 (30.0)

6.4

23.9

14 (70.0)

3 (15.0)

Mucinous tubular and spindle

4 (20.0)

Unclassified

4 (20.0)

Translocation

2 (10.0)

Chromophobe

0

Bellini duct

0

ACD-associated

0

ICI + TKI

24

4/20

65.0

(29.0–86.0)

Papillary

9 (37.5)

CR: 0

PR: 10 (41.6)

SD: 9 (37.5)

PD: 5 (20.9)

8.8

26.8

23 (95.8)

12 (50.0)

Mucinous tubular and spindle

0

Unclassified

3 (12.5)

Translocation

4 (16.7)

Chromophobe

3 (12.5)

Bellini duct

2 (8.3)

ACD-associated

3 (12.5)

Toyoda21

(2024)

ICI + ICI

39

34/5

65.0

(27.0–86.0)

Papillary

20 (55.5)

CR: 3 (7.6)

PR: 7 (46.6)

SD: 9 (23.0)

PD: 13 (33.3)

5.4

24.2

-

-

Unclassified

3 (8.3)

ACD-associated

1 (2.7)

MIT family translocation

1 (2.7)

Chromophobe

1(2.7)

ICI + TKI

36

23/13

65.5

(26.0–87.0)

Papillary

20 (55.5)

CR: 2 (5.6)

PR: 11 (30.6)

SD: 13 (36.1)

PD: 3 (8.3)

5.6

23.4

-

-

Unclassified

3 (8.3)

ACD-associated

1 (2.7)

MIT family translocation

1 (2.7)

Chromophobe

1(2.7)

Present study

ICI + ICI

11

5/6

62.0

(58.0–75.0)

Papillary

9 (81.8)

CR: 2 (18.1)

PR: 3 (27.3)

SD: 3 (27.3)

PD: 3 (27.3)

11.5

23.5

8 (72.7)

1 (9.1)

Chromophobe

2 (18.2)

ACD-associated

0

MIT family translocation

0

FH-deficients

0

ICI + TKI

10

8/2

55.0

(50.3–72.5)

Papillary

6 (60.0)

CR: 1 (10.0)

PR: 5 (50.0)

SD: 2 (20.0)

PD: 2 (20.0)

NR

NR

10 (100)

4 (40.0)

Chromophobe

0

ACD-associated

2 (20.0)

MIT family translocation

1 (10.0)

FH-deficients

1 (10.0)

  1. Abbreviations: ACD = Acquired cystic disease; BOR = Best Overall Response; CR = Complete response; FH = Fumarate Hydratase; HLRCC = Hereditary Leiomyomatosis and Renal Cell Carcinom; ICI = Immune Checkpoint Inhibitor; MIT family = Microphthalmia Transcription factor family; mo = Months; n = Number; OS = Overall survival; PD = Progressive disease; PFS; Progression-Free Survival; PR = Partial response; SD = Stable disease; TKI = Tyrosine Kinase Inhibitor; TRAE = Treatment related adverse events.
Back to article page